Cancer Supportive Care Drug Development Pipeline Review, 2017

Thursday, February 8, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Cancer Supportive Care Drug Development Pipeline Review, 2017

NEW YORK, Fev. 8, 2018 /PRNewswire/ -- SummaryRead the full report: https://www.reportlinker.com/p05236700 Anorexia is defined as the

loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia-cachexia and asthenia, which is associated with weakness, fatigue, and a poor quality of life. There are a total of 24 products in development for this indication, by 18 companies and four academic institutions.Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. There are a total of 32 products in development for this indication, by 22 companies and four academic institutions. Key companies operating in this pipeline space include MetCure Therapeutics, Applied Integrin Sciences, Eli Lilly, and Tel Aviv University.Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. There are a total of 52 products in development for this indication, by 40 companies and four academic institutions. Key companies operating in this pipeline space include Komipharm, Trillium Therapeutics, AstraZeneca, Insys Therapeutics, Klaria Pharma and Pharmaleads.The majority of products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1, although there are a range of other molecular targets in development. Within bone metastasis, the most common molecular targets are the tumor necrosis factor ligand superfamily member 11, and the hepatocyte growth factor receptor, along with a range of others. Finally, within cancer pain, neurotransmitters such as the mu type opioid receptor, and a range of ion channels, are the most common type of target, reflecting the pain treatment landscape in general.This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, and features dormant and discontinued projects.Scope- Which companies are the most active within each pipeline?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in this disease area?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05236700 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com  US: (339)-368-6001 Intl: +1 339-368-6001 

Cision View original content:http://www.prnewswire.com/news-releases/cancer-supportive-care-drug-development-pipeline-review-2017-300595940.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store